MAIN COMPONENTS OF THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET IN GLIOBLASTOMA

Favorite this paper
How to cite this paper?
Details
  • Presentation type: MS - Master's student
  • Track: 2. Cellular Biology
  • Keywords: Glioblastoma; Endocannabinoid System; AM251; CB1;

Authors:

  • 1 Universidade Federal do Rio de Janeiro

Please log in to watch the video

Log in
Abstract

INTRODUCTION AND OBJECTIVES: Glioblastoma (GBM) is the most malignant tumor of the Central Nervous System (grade IV), and it is origin is glial cells, it presents rapid proliferation, high heterogeneity and angiogenic activity. Due to these characteristics, it is resistant to current therapies, which fail to have a significant impact on the short survival rate of individuals affected by this tumor. Therefore, the search for new antitumor therapies is necessary. And the endocannabinoid system has shown promising results, as the activation of its receptors has shown, for example, the inhibition of cell growth, increased apoptosis, inhibition of cell migration and invasion in cell cultures isolated from tumors of patients with GBM. This system is composed of CB1 and CB2 receptors and two better elucidated endocannabinoids, anandamide (AEA) and 2-arachidonoyl-glycerol. In addition to these, other exogenous substances can modulate, activate or block CB1 and CB2 receptors, the cannabinoid agonists and antagonists. Some studies have already demonstrated the overexpression of CB1 and CB2 receptors in GBM cells, which may indicate a promising therapeutic target. Therefore, our work intends to evaluate the activity of the receptor belonging to the endocannabinoid system, CB1, in a strain of GBM (GBM02), obtained by surgical resection. MATERIAL AND METHODS: To verify the sensitivity of GBM02 cells to the treatment of AEA agonist and AM251 antagonist, a mitochondrial activity assay (MTT) was performed, indirectly used to check cell viability. For this, a concentration of 1.5 x 104 of GBM02 cells was used, which were treated with AEA (0.5 µM - 25 µM) and AM251 (0.5 µM - 10 µM) for 24 and 48 hours. Cells were also plated at concentrations of 1.0 x 104, 1.5 x 104 or 2.0 x 104 and treated with AM251 (5µM and 10µM). Triplicates were analyzed for each condition and the obtained absorbance values were normalized by the value obtained in the control condition (vehicle - DMSO). And to assess the morphological alteration and the total number of GBM02 cells after treatment with AM251 (5µM and 10 μM) for 24 and 48 hours, the F-actin cytoskeleton labeling with Phalloidin was used. RESULTS AND CONCLUSION: The results obtained showed a significant decrease in mitochondrial activity compared to the control, through MTT assays, of GBM02 cells in the presence of 10µM AM251. It has also been shown that this decrease is dependent on cell concentration. Furthermore, a relationship was observed between the alteration in the morphology of these cells, through the labeling of the cytoskeleton of F-actin by Phalloidin, and the decrease in their total number when treated with 10µM of AM251 in relation to the control. In short, our results could help to explore a possible new therapeutic target for patients affected by GBM.

Questions (1 topic)

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Author

Isabelle Medeiros Braga

Olá, Boa tarde! Tudo bem? Muito obrigada!! Pretendemos sim investigar o receptor CB2, além do CB1. E ainda investigar o papel desses receptores em outras linhagens de GBM, tanto comerciais quanto outras linhagens  estabelecida pelo nosso laboratório. Além disso, pretendemos também realizar uma comparação do funcionamento desses receptores a partir de antagonistas em agonistas nas linhagens de GBM que mencionei e em uma linhagem de astrocitos normais (como controle).

Lucas Delmonico

Vocês pretendem avaliar esses receptores de forma molecular, por exemplo, qPCR? 

Author

Isabelle Medeiros Braga

Inicialmente nós pretendemos realizar um blotting, mas também seria interessante ver a expressão gênica.

Lucas Delmonico

Obrigado!